Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 31, 2022
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical studies in murine and a naturally-occurring feline model of GM1 gangliosidosis have supported AXO-AAV-GM1’s ability to increase β-galactosidase enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and exten...
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 21, 2021
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-AAV-GM1, the company’s adeno-associated viral vector (AAV)9-based gene therapy for the treatment of Type I (early infantile onset) and Type II (late infantile and juvenile onset) GM1 gangliosidosis.
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 04, 2021
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : National Human Genome Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Initial data from the ongoing Phase 1/2 study in five patients in the low-dose cohort showed that AXO-AAV-GM1 was generally well tolerated with a favorable safety profile and provide early indications of clinical disease stability.
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 15, 2020
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : National Human Genome Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AXO-AAV-GM2
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA indicating that it has satisfactorily addressed all issues related to the clinical hold.
Brand Name : AXO-AAV-GM2
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 09, 2020
Lead Product(s) : AXO-AAV-GM2
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Oxford Biomedica
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-Lenti-PD gene therapy demonstrate consistent treatment outcomes including Favorable safety and tolerability profile, with no serious adverse events attributable to gene therapy; Improvement in Hauser diary “Good ON time” and “OFF time” and ot...
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 29, 2020
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Oxford Biomedica
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-AAV-GM1 is the first gene therapy to enter clinical trials for GM1 gangliosidosis and the company believes that it has the potential to provide meaningful clinical benefit to both Type I and Type II patients.
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 09, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months. EXPLORE-PD, a randomized, sham-controlled study of AXO-Lenti-PDis expected to begin dosing in 2021.
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 06, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Recipient : Viralgen
Deal Size : Undisclosed
Deal Type : Partnership
Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership
Details : Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercial...
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 15, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Recipient : Viralgen
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Agreement
Details : Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiV...
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 31, 2020
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?